Akanda (STU:Y232) EBIT: €-39.68 Mil (TTM As of Dec. 2025)


STU:Y232 Akanda Corp STU:Y232
21 GF Score
Price €68.55
! 9 Warning Signs
View Full Analysis

What is Akanda EBIT?

Akanda STU:Y232 21 EBIT is €-39.68 Mil as of Dec. 2025. GuruFocus rates STU:Y232 with a GF Score™ of 21/100. The stock has 9 warning signs investors should review.

Akanda's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-38.48 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-39.68 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Akanda's annualized ROC % for the quarter that ended in Dec. 2025 was -177.85%. Akanda's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3,412.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Akanda's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -218.69%.

Akanda  (STU:Y232) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Akanda's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-5.966 * ( 1 - 0% )/( (2.573 + 4.136)/ 2 )
=-5.966/3.3545
=-177.85 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.388 - 2.187 - ( 2.188 - max(0, 2.465 - 3.093+2.188))
=2.573

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.291 - 3.373 - ( 0.43 - max(0, 5.294 - 3.076+0.43))
=4.136

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Akanda's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-76.954/( ( (2.296 + max(-2.146, 0)) + (2.214 + max(-1.839, 0)) )/ 2 )
=-76.954/( ( 2.296 + 2.214 )/ 2 )
=-76.954/2.255
=-3,412.59 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.042) - (2.187 + 0 + 0.00099999999999989)
=-2.146

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.084 + 0 + 1.45) - (3.373 + 0 + -8.8817841970013E-16)
=-1.839

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Akanda's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-39.68/18.144
=-218.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akanda EBIT Related Terms

Akanda EBIT Historical Data

* Premium members only.

The historical data trend for Akanda's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akanda EBIT Chart

Akanda Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -2.18 -7.67 -3.29 -3.09 -39.66

Akanda Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.90 -2.06 -0.97 -1.20 -38.48

STU:Y232 vs BFRI, BIOE, CABR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akanda's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akanda EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akanda's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Akanda's EV-to-EBIT falls into.


STU:Y232
21GF Score
Akanda Corp STU:Y232
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akanda EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-39.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-39.68 Mil mean?
Akanda (STU:Y232) has a EBIT of €-39.68 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Akanda.
Is Akanda's EBIT too high?
Akanda's current EBIT is €-39.68 Mil. Overall, Akanda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Akanda's EBIT compare to BFRI and BIOE?
Akanda's EBIT of €-39.68 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Akanda. Akanda's current EBIT is €-39.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akanda stock overvalued right now?
Akanda (STU:Y232) has a current EBIT of €-39.68 Mil. The current EBIT is €-39.68 Mil. Akanda's overall GF Score™ is 21/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Akanda (STU:Y232), the current EBIT is €-39.68 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akanda Business Description

Other Exchanges AKAN:USAY232:Germany
Address c/o Gowling WLG (Canada) LLP, 100 King Street W, Suite 1600, Toronto, ON, CAN, M5X 1G5
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
21GF Score

Get the complete analysis for STU:Y232

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.55
Price